Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript [Seeking Alpha]
Athira Pharma, Inc. (ATHA)
Company Research
Source: Seeking Alpha
Company Participants Julie Rathbun - Head of Investor Relations Mark Litton - President, CEO & Director Javier San Martin - Chief Medical Officer Kevin Church - Chief Scientific Officer Conference Call Participants David Portman - Sermonix Pharmaceuticals, Inc. Presentation Operator Hello, ladies and gentlemen. Thank you for standing by, and welcome to the Athira Pharma conference call. [Operator Instructions] Please be advised that today's conference call may be recorded. I would now like to hand the conference call over to Julie Rathbun, Head of Investor and Public Relations with Athira, please go ahead. Julie Rathbun Head of Investor Relations Thank you, operator. Good morning, and welcome to the Athira Pharma conference call to discuss the transformative transactions announced in this morning's press release, joining us today are Dr. Mark Litton, President and CEO; Dr. Javier San Martin, Chief Medical Officer; Dr. Kevin Church, Chief Scientific Officer; Ro
Show less
Read more
Impact Snapshot
Event Time:
ATHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATHA alerts
High impacting Athira Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ATHA
News
- Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million [Yahoo! Finance]Yahoo! Finance
- Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 MillionGlobeNewswire
- Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Athira Pharma (NASDAQ:ATHA) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
ATHA
Earnings
- 8/7/25 - In-Line
ATHA
Sec Filings
- 12/18/25 - Form SCHEDULE
- 12/18/25 - Form 8-K/A
- 12/18/25 - Form 8-K
- ATHA's page on the SEC website